Low-Dose Sulfonylureas
Reviewed by CDE Mehandi Sharma · Updated
The treatment that makes a monogenic diagnosis worth having is, in the two commonest Indian subtypes, an old and inexpensive class of tablet.
Sulfonylureas — glibenclamide, gliclazide and others — stimulate the beta cell to release insulin. In HNF1A and HNF4A-MODY they work particularly well because they act through a route that bypasses the pathway the faulty gene affects. Both subtypes show increased sensitivity to them, and low doses produced better glucose control than metformin in HNF4A-MODY.
Three things follow that matter practically.
Low doses are the point, not a starting compromise. People with these subtypes are unusually sensitive to sulfonylureas, so a standard Type 2 dose can be far too much. Treatment usually starts low deliberately.
Hypoglycemia is the main risk. Because of that sensitivity, starting too high causes lows — which is why the dose is built up cautiously and why you need to know how to recognise and treat one.
Availability is good in India. Sulfonylureas are among the cheapest and most widely stocked diabetes tablets here, which makes this one of the rare situations where the better treatment is also the more affordable one.
Durability is not unlimited. These subtypes progress, so a sulfonylurea that works well may eventually need support.